Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

3-D irradiation of brain cancer in children spares IQ, memory, other cognitive functions

06.08.2004


Encouraging results of Phase II conformal radiation trial for ependymoma could resolve the dilemma on whether to withhold therapeutic radiation from children to preserve their cognitive development

A radiation therapy technique that kills brain tumors in children while sparing normal tissue allows young patients to enjoy normal development of memory, reasoning, problem-solving and other cognitive functions, according to investigators at St. Jude Children’s Research Hospital. The results of a Phase II clinical trial of this technique, called conformal radiation therapy (CRT), hold promise for sparing cognitive development even in children younger than three years.

This research is published in the August issue of the Journal of Clinical Oncology. The St. Jude study found that about 75 percent of the children treated for ependymoma with CRT did not experience progression of their cancer after three years, and their cognitive development was not significantly impaired by radiation therapy.



Ependymoma is a malignant brain tumor that occurs predominately in children. About 150 cases occur in the United States each year among people younger than 14 years.

The study’s findings could offer an answer to a long-standing dilemma facing physicians treating children who have brain tumors, according to Thomas Merchant, D.O., Ph.D., chief of Radiation Oncology at St. Jude. Following surgery to remove as much of the tumor as possible, radiation treatment is more effective than chemotherapy at eradicating the remaining cancer. However, despite its lower rate of treatment success, chemotherapy has been used in the past for young children because of fear among physicians and parents of radiation-related treatment effects.

Merchant is the principal investigator and lead author of the JCO report.

"The long-term problems with cognitive development caused by traditional radiation therapy make this treatment unpopular among both physicians and parents," Merchant said. "However, the improved outcomes we have seen in both disease control and intellectual development using CRT suggest that it might be possible to reintroduce the routine use of radiation therapy as a treatment option even for very young children."

Merchant is currently principal investigator for a national trial of CRT for ependymoma based on the study’s findings. The trial is conducted by the Children’s Oncology Group.

CRT combines CAT scans and MRI to create pictures of the cancer that a computer then turns into three-dimensional images of the tumor exactly as it appears in the brain. These images are combined with computer-controlled radiation beams and meticulous positioning of the treatment table on which the patient lies. Radiation hits the tumor at precisely calculated angles and depths matching the 3-D image of the tumor, obliterating the cancer and sparing healthy tissue.

The median age of the 88 patients in the St. Jude study was 2.85 years, and 48 patients were younger than three years. According to Merchant, the inclusion of children younger than 3 years at the time of irradiation was unique, since children in this age group are at greatest risk of the effects of irradiation.

Before CRT, all patients underwent surgery to remove as much tumor as possible. Patients underwent testing of their cognitive abilities before CRT and again at six, 12, 24, 36, 48 and 60 months after start of radiation therapy. The tests varied according to age and included assessments of IQ, verbal memory and recall, academic achievement and other developmental skills that could be disrupted by radiation damage to the brain.

Merchant attributes the encouraging results of the study to three factors: 1) the large number of patients that underwent extensive surgery to remove most of the tumor before irradiation therapy; 2) the use of CRT to target tumors; and 3) the relatively high dose of radiation that could be used with CRT without jeopardizing healthy brain tissue.

Bonnie Cameron | EurekAlert!
Further information:
http://www.stjude.org

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>